Neutrophil Extracellular Traps in CML: Insights into Tyrosine Kinase Inhibitor Effects

Study Background and Research Question

Chronic myeloid leukemia (CML) is characterized by the presence of the BCR-ABL1 fusion oncogene, resulting from the Philadelphia chromosome translocation. The therapeutic landscape for CML has been revolutionized by tyrosine kinase inhibitors (TKIs), which target the constitutive kinase activity of BCR-ABL1. While agents such as imatinib and next-generation TKIs like dasatinib and ponatinib have greatly improved patient outcomes, their use has also brought to light new complications, particularly cardiovascular adverse events. The biological basis for these toxicities remains incompletely understood. Recent attention has turned to neutrophil extracellular traps (NETs)—web-like DNA-protein structures released by neutrophils during a specific form of cell death known as NETosis. NETs are implicated in both immune defense and prothrombotic states. The central research question of Telerman et al. was whether NET formation is altered in CML and how different TKIs modulate this process, potentially contributing to vascular risks observed in clinical practice.

Key Innovation from the Reference Study

The study by Telerman et al. delivers a dual innovation: first, it provides direct quantitative evidence that NET formation is significantly increased in neutrophils from CML patients compared to healthy controls; second, it demonstrates that different TKIs, particularly ponatinib, further modulate NET production in a drug-specific manner. This mechanistic insight suggests that NETs may serve as a previously underappreciated link between TKI therapy and vascular toxicity in CML patients. By dissecting these pathways, the study opens avenues for predictive biomarkers and safer therapeutic approaches in leukemia management.

Methods and Experimental Design Insights

• Patient and Control Cohorts: The study enrolled treatment-naïve CML patients and age-matched healthy controls. Peripheral blood neutrophils were isolated using standard gradient separation.
• NET Induction and Quantification: Neutrophils were exposed to classical NET inducers—ionomycin (IO) and phorbol 12-myristate 13-acetate (PMA). NET release was quantified by measuring extracellular DNA and by immunofluorescent detection of NET-associated proteins such as citrullinated histone H3 (H3cit) and myeloperoxidase (MPO).
• Treatment with TKIs: Neutrophils were pre-treated with various TKIs, including ponatinib, nilotinib, and others, to assess their impact on NET formation.
• Mechanistic Pathway Probing: To dissect the intracellular drivers of NETosis, inhibitors such as Cl-amidine (PAD4 inhibitor) and diphenyleneiodonium (NADPH oxidase inhibitor) were used. The team further leveraged a BCR-ABL1-transduced HoxB8-immortalized mouse progenitor cell line, which recapitulates neutrophil differentiation and NET formation ex vivo.

Protocol Parameters

• Neutrophil isolation: Human peripheral blood collected in EDTA tubes; neutrophils separated by density gradient centrifugation.
• NET stimulation: Ionomycin (1 μM) or PMA (100 nM) for 3 hours at 37°C; NET release quantified by extracellular DNA and protein markers.
• TKI pretreatment: Neutrophils exposed to ponatinib, nilotinib, or other TKIs at clinically relevant concentrations for 1 hour before NET stimulation.
• PAD4 inhibition: Cl-amidine added at 100 μM during NET induction assays to block citrullination-dependent NETosis.
• Cell line model: HoxB8-BCR-ABL1 mouse progenitors differentiated in vitro for mechanistic validation; NETs assessed by H3cit and MPO expression.

Core Findings and Why They Matter

The study found that neutrophils from CML patients exhibited a pronounced tendency to form NETs—both at baseline and when stimulated with IO or PMA—relative to healthy controls. This was accompanied by elevated levels of key NETosis markers, including H3cit and PAD4, as well as increased generation of reactive oxygen species (ROS). Notably, among the TKIs tested, ponatinib significantly increased NET-associated elastase and ROS production beyond that seen with other agents. Mechanistically, NET formation in this context was shown to be PAD4-dependent, as Cl-amidine effectively suppressed NET release, whereas NADPH oxidase inhibition had no significant effect. The findings extend to experimental models, with BCR-ABL1-transduced HoxB8-derived neutrophils recapitulating increased NETosis that was sensitive to PAD4 inhibition.

These results highlight a novel prothrombotic mechanism potentially explaining the increased vascular risk observed with certain TKIs, especially ponatinib. The implication is that NET formation, modulated by both leukemia biology and TKI therapy, may become a biomarker or therapeutic target for mitigating cardiovascular complications in CML management.

Comparison with Existing Internal Articles

Several recent reviews and research updates provide complementary perspectives on these findings:

• The article "Dasatinib Monohydrate: Unraveling Kinase Networks and NET Biology" explores how multitargeted kinase inhibitors like dasatinib contribute to advanced dissection of NET-driven pathways in chronic myeloid leukemia research. It contextualizes the current findings within broader kinase network interrogation, emphasizing the value of understanding TKI-specific effects on leukocyte function.
• "Dasatinib Monohydrate: Charting the Next Frontier in Multitargeted Kinase Inhibition" discusses emerging translational models, including the impact of TKI-mediated modulation of NETs, and offers practical recommendations for integrating such evidence into the design of preclinical and assembloid models.
• Both reviews reinforce the importance of considering not just antiproliferative efficacy but also immunomodulatory and vascular effects when selecting TKIs for laboratory research or clinical translation.

Limitations and Transferability

The study by Telerman et al. is primarily ex vivo and in vitro in nature, using neutrophils from treatment-naïve CML patients and murine cell line models. While these approaches provide mechanistic clarity, they may not fully capture the complexity of in vivo human vascular biology or the chronic effects of long-term TKI exposure. Furthermore, while ponatinib showed the most pronounced effect on NET formation, the study did not directly evaluate dasatinib or all available TKIs in comparative long-term models. Therefore, while the link between TKI therapy, NETs, and vascular risk is strengthened, further clinical and translational studies are warranted to determine the predictive and therapeutic value of NET modulation in CML and related contexts.

Research Support Resources

For researchers investigating kinase signaling, imatinib-resistant BCR-ABL inhibition, or the interplay between TKIs and immune cell function in chronic myeloid leukemia research, robust reagents are essential. Dasatinib Monohydrate (BMS-354825, SKU B5954) is a well-characterized, multitargeted ATP-competitive inhibitor that enables precise modulation of ABL, SRC, and related kinases in both cellular and biochemical models. Its use is documented in studies exploring both antiproliferative and immunoregulatory effects, and it is available from APExBIO for advanced experimental workflows. Researchers can leverage such high-quality inhibitors to extend findings from NET biology to broader translational or resistance-focused studies.